Prognosis After Revascularization Therapy in the Dijon Ischemic Stroke Evaluation Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 821
- 试验地点
- 2
- 主要终点
- Rate of handicap
研究概览
简要总结
The current management of ischemic stroke is based on different strategies that may be combined: intravenous thrombolysis in a stroke ICU, intravenous thrombolysis in a telemedicine procedure, endovascular thrombectomy. Given this now rich therapeutic arsenal, it seems necessary to evaluate practices in local care in the field and the impact of these on the prognosis of ischemic stroke victims. The aim of this observational study is to compare these different care practices without interfering with the choice of strategy.
A blood sample will also be taken at different times to study the value of growth differentiation factors (GDF) 8, 11 and 15, and Brain-derived Neurotrophic Factor as prognostic biomarkers
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with symptomatic ischemic stroke defined according to WHO criteria and treated by intravenous thrombolysis at the stroke ICU at Dijon CHU, intravenous thrombolysis by telemedicine with subsequent transfer to the Dijon stroke ICU, and/or endovascular thrombectomy at Dijon CHU)
- •Patients aged over 18 years.
- •Patients who have provided written informed consent to take part in the study.
排除标准
- •Patients who refuse to take part in the study.
- •Subjects in custody.
- •Patients (or a person of trust) who cannot be contacted by telephone during the follow-up.
结局指标
主要结局
Rate of handicap
时间窗: 6 months
次要结局
- Serum levels of biomarkers of stress(Changes compared with baseline levels at Day 1, Day 3, Day 7)
